Hyperuricemia, gout and the kidney

Current Opinion in Rheumatology

Volumn 24, Issue 2, 2012, Pages 127-131

  Gibson, Terence ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

allopurinol; chronic kidney disease; febuxostat; gene mutation; renal tubule; urate transporter; uromodulin

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; COLCHICINE; FEBUXOSTAT; GLUCOSE TRANSPORTER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OTERACIL; TAMM HORSFALL GLYCOPROTEIN; URATE; URATE OXIDASE; URIC ACID;

CHROMOSOME 2P; CHRONIC KIDNEY DISEASE; CILIATED EPITHELIUM; DISEASE COURSE; FAMILIAL DISEASE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GLOMERULUS FILTRATION RATE; GOUT; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY FAILURE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; NEPHROLITHIASIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SLC2A9 GENE; URIC ACID BLOOD LEVEL; URIC ACID NEPHROPATHY; VASCULAR DISEASE;

GOUT; HUMANS; HYPERURICEMIA; KIDNEY FAILURE, CHRONIC; URIC ACID;

EID: 84857051665     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32834f049f     Document Type: Review

References (30)

1. Arram Z, Krishnan E. Hyperuricaemia: Where nephrology meets rheumatology. Rheumatology 2008; 47:960-964. (Pubitemid 351865915)
2. Anzai N, Ichida K, Jutabha P, et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URAT1 (SLC2A9) in humans. J Biol Chem 2008; 283:26834-26838.
3. Levinson D, Sorensen LB. Renal handling of uric acid in normal and gouty subjects: Evidence for a 4-component system. Ann Rheum Dis 1980; 39:173-179. (Pubitemid 10111779)
4. Gibson T, Sims HP, Jimenez SA. Hypouricaemia and increased renal urate clearance associated with hyperparathyroidism. Ann rheum Dis 1976; 35:372-376.
5. Gibson T, Highton J, Potter C, et al. Renal impairment and gout. Ann Rheum Dis 1980; 39:417-423. (Pubitemid 10005929)
6. Gibson T, Rodgers A, Simmonds H, Toseland P. Beer drinking and its effect on uric acid. Br J Rheumatol 1984; 23:203-209. (Pubitemid 14089882)
7. Dehgan A, Kottgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: A genome-wide association study. Lancet 2008; 372:1953-1961.
8. Hollis-Moffat JE, Xu X, Dalbeth N, et al. Role of the urate transporter SLC2A9 gene in susceptibility to gout in New Zealand Maori, Pacific Island and Caucasian case-control sample sets. Arthritis Rheum 2009; 60:3485-3492.
9. Tu HP, Chen CJ, Tovosia S, et al. Associations of a nonsynonymous variant in SLC2A9 with gouty arthritis and uric acid levels in Han Chinese subjects and Solomon Islanders. Ann Rheum Dis 2010; 69:887-890. Using four SNPs of the SLC2A9 gene which codes for the renal tubular transporter GLUT9, an association with gout susceptibility was identified in Han Chinese and Melanesian populations.
10. Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40:437-442. (Pubitemid 351450879)
11. Rule A, de Andrade M, Matsumoto M, et al. Associations between SLC2A9 transporter gene variants and uric acid photypes in African American and white families. Rheumatology 2011; 50:871-878. Fifty-three SNPs of SLC2A9 gene were associated with serum urate in black and 63 in white American populations but could not be linked to renal urate excretion.
12. Enomoto A, Ki mura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417:447-452. (Pubitemid 34563537)
13. Ichida K, Hosoyamada M, Kamatani N, et al. Age and origin of the G774A mutation in SLC22A12 causing renal hypouricemia in Japanese. Clinic Genet 2008; 74:243-251.
14. Dinour D, Gray Nk, Campbell S, et al. Homozygous SLC2A9 mutations cause severe renal hypouricemia. J Am Soc Nephrol 2010; 21:4-72. Homozygous mutations of the SLC2A9 gene were associated with hereditary hypouricemia in a single family similar to earlier descriptions of mutations of the SLC22A12 gene which encodes for the first transporter to be described, URAT1.
15. Bleyer A, Zivna M, Kmoch S. Uromodulin associated kidney disease. Nephron Clin Pract 2011; 118:31-36.
16. Warren D, Simmonds H, Gibson T, Naik R. Familial gout and renal failure. Arch Dis Children 1981; 56:699-704.
17. Schaffer P, Gombos E, Meichelbeck K, et al. Childhood course of renal insufficiency in a family with a uromodulin gene mutation. Pediatr Nephrol 2010; 25:1355-1360.
18. Lee D, Kim J, Oh S, et al. A case of familial juvenile hyperuricemic nephropathy with novel uromodulin gene mutation, a novel heterozygous missense mutation in Korea. J Korean Med Sci 2010; 25:1680-1682.
19. Zaucke F, Boehnlein J, Steffens, et al. Uromodulin is expressed in renal primary cilia and UMOD mutations result in decreased ciliary uromodulin expression Hum Mol Genet 2010; 15:1985-1997. The uromodulin gene (UMOD) was shown to be expressed on the cilia of proximal tubules and was reduced in amount compared with normals in renal biopsies of patients with uromodulin-related nephropathy.
20. Piret S, Danoy P, Dahan K, et al. Genome-wide study of familial juvenile hyperuricaemic (gouty) nephropathy (FJHN) indicates a new locus FJHN3 linked to chromosome 2p22.11-p21. Hum Genet 2011; 129:51-58. In a genome-wide linkage study of uromodulin-related FJHN, a novel locus was identified on chromosome 2p22.1021.
21. Gibson T, Hannon S, Hatfield P, et al. The effect of acid loading on renal excretion of uric acid and ammonium in gout. Adv Exp Med Biol 1977; 76B:46-55.
22. Kang D, Nakagawa T, Fen L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13:2888-2897. (Pubitemid 35386908)
23. Nakaya I, Namikoshi T, Tsuruta Y, et al. Management of asymptomatic hyperuricemia in patients with chronic kidney disease by Japanese nephrologists: A questionnaire survey. Nephrology 2011; 16:518-521.
24. Gibson T, Highton J, Simmonds H, Potter C. Hypertension, renal function and gout. Postgrad Med J 1979; 55(Suppl 3):21-25. (Pubitemid 10245440)
25. Kanbay M, Solak Y, Dogan E, et al. Uric acid in hypertension and renal disease: The chicken or the egg? Blood Purif 2010; 30:288-295.
26. Sanchez-Lozada L, Tapia E, Soto V, et al. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricemia. Nephrol Dial Transplant 2008; 4:1179-1185. (Pubitemid 351767502)
27. Gibson T, Rodgers V, Potter C, et al. Allopurinol treatment and its effect on renal function in gout: A controlled study. Ann Rheum Dis 1982; 41:59-65. (Pubitemid 12136653)
28. Goicoechea M, de Vinuesa S, Verdalles V, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5:1388-1393. Fifty-seven hyperuricemic patients with impaired renal function were treated with allopurinol over 2 years and compared with 56 matched controls. Renal function stabilized in the allopurinol group but declined in the controls.
29. Schumacher H, Becker M, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the focus efficacy and safety study. Rheumatology (Oxford) 2009; 48:188-194.
30. Whelton A, Macdonald P, Zhao L, et al. Renal function in gout: Long term treatment effects of febuxostat. J Clin Rheumatol 2011; 17:7-13.